{"id":"calcium-dobesilate","rwe":[{"pmid":"41864866","year":"2026","title":"Effect of calcium dobesilate on intraretinal cysts and exudates in non-proliferative diabetic retinopathy: a Fiji ImageJ analysis.","finding":"","journal":"BMC ophthalmology","studyType":"Clinical Study"},{"pmid":"41821279","year":"2026","title":"Effect of calcium dobesilate on liver regeneration in rats undergoing partial hepatectomy.","finding":"","journal":"Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES","studyType":"Clinical Study"},{"pmid":"41634981","year":"2026","title":"Calcium Dobesilate Interference in Two Urinary Total Protein Detection Methods.","finding":"","journal":"Journal of clinical laboratory analysis","studyType":"Clinical Study"},{"pmid":"41564121","year":"2026","title":"The Efficacy of Calcium Dobesilate Alone or with Vascularized Lymph Node Transfer in Lymphedema Treatment: A Preliminary Study.","finding":"","journal":"Plastic and reconstructive surgery","studyType":"Clinical Study"},{"pmid":"41523513","year":"2025","title":"Diverse and Atypical Presentations of Acroangiodermatitis of Mali: Diagnostic Insights From Three Cases.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"tags":[{"label":"calcium dobesilate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C05BX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetic retinopathy","category":"indication"},{"label":"Coagulants","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Hemostatics","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Glycosuria","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperglycemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Polydipsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Polyuria","drugRate":"","severity":"common","organSystem":""},{"effect":"SAP enzyme elevations","drugRate":"","severity":"common","organSystem":""},{"effect":"SGPT enzyme elevations","drugRate":"","severity":"common","organSystem":""},{"effect":"Eosinopenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Euphoria","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Improvement of attitude","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Cushing's Syndrome","drugRate":"","severity":"serious"},{"effect":"Laminitis","drugRate":"","severity":"serious"},{"effect":"Retardant effect on wound healing","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CALCIUM DOBESILATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:02:14.840945+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:02:21.645809+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCIUM DOBESILATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:02:21.995715+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2106191/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:02:22.894332+00:00"}},"allNames":"dexium","offLabel":[],"synonyms":["dobesilate","calcium dobesilate","dexium","dobesilate calcium","doxium","hydroquinone calcium sulfate","hydroquinone calcium sulfonate","calcium doxybensylate"],"timeline":[],"brandName":"Dexium","ecosystem":[{"indication":"Diabetic retinopathy","otherDrugs":[{"name":"ranibizumab","slug":"ranibizumab","company":"Genentech"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"calcium dobesilate","explanation":"","oneSentence":"","technicalDetail":"Calcium Dobesilate is believed to exert its effects through the inhibition of platelet aggregation and the improvement of endothelial function, leading to reduced vascular permeability and inflammation in the retina."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/936","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CALCIUM%20DOBESILATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCIUM DOBESILATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:07:25.268426","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:02:25.423942+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"calcium dobesilate","indications":{"approved":[{"name":"Diabetic retinopathy","source":"DrugCentral","snomedId":4855003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT07494136","phase":"PHASE4","title":"Dose Dependent Steroid Injections","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05","conditions":["Lumbar Radiculopathy","Sciatica","Back Pain With Radiation"],"enrollment":150,"completionDate":"2027-05"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":["Recurrent AL Amyloidosis","Refractory AL Amyloidosis"],"enrollment":24,"completionDate":"2026-06-30"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":525,"completionDate":"2026-09-18"},{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":["Multiple Myeloma"],"enrollment":28,"completionDate":"2027-06-01"},{"nctId":"NCT05519085","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Celgene","startDate":"2022-09-20","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":810,"completionDate":"2033-11-30"},{"nctId":"NCT06235567","phase":"PHASE1,PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT01297764","phase":"PHASE1,PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":["Multiple Myeloma"],"enrollment":17,"completionDate":"2026-07"},{"nctId":"NCT02773030","phase":"PHASE1,PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":["Multiple Myeloma"],"enrollment":466,"completionDate":"2028-07-28"},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":["Marginal Zone Lymphoma(MZL)"],"enrollment":65,"completionDate":"2029-10-02"},{"nctId":"NCT02491632","phase":"PHASE2,PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":["Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":["Clonal Cytopenia of Undetermined Significance","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia"],"enrollment":80,"completionDate":"2033-11-02"},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":["Multiple Myeloma"],"enrollment":75,"completionDate":"2031-03"},{"nctId":"NCT06207123","phase":"PHASE1,PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":["Acute Leukemia","Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":15,"completionDate":"2026-12-01"},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma"],"enrollment":53,"completionDate":"2029-03-30"},{"nctId":"NCT05552976","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-10","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":525,"completionDate":"2029-07-25"},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":["Multiple Myeloma"],"enrollment":30,"completionDate":"2026-07"},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":30,"completionDate":"2031-12-31"},{"nctId":"NCT06348108","phase":"PHASE1","title":"Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alfred Chung, MD","startDate":"2025-07-28","conditions":["Multiple Myeloma","Refractory Multiple Myeloma","Relapsed Multiple Myeloma"],"enrollment":32,"completionDate":"2029-07-31"},{"nctId":"NCT03661645","phase":"PHASE4","title":"Post-operative Methylprednisolone Taper Course for Orthopedic Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Emory University","startDate":"2018-09-07","conditions":["Orthopedic Surgeries"],"enrollment":500,"completionDate":"2029-01"},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":["Multiple Myeloma"],"enrollment":33,"completionDate":"2026-05-07"},{"nctId":"NCT01572480","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":["Multiple Myeloma"],"enrollment":55,"completionDate":"2025-02-28"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT06104449","phase":"PHASE1","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-14","conditions":["Prostatic Neoplasms","Metastatic Castration-Resistant Prostate Cancer"],"enrollment":6,"completionDate":"2026-04-20"},{"nctId":"NCT05730036","phase":"PHASE3","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-09-18","conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"enrollment":410,"completionDate":"2033-04-19"},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":3,"completionDate":"2026-08-31"},{"nctId":"NCT04094961","phase":"PHASE1,PHASE2","title":"Ixazomib + Pomalidomide + Dexamethasone In MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2019-09-18","conditions":["Multiple Myeloma","Multiple Myeloma in Relapse"],"enrollment":52,"completionDate":"2027-01-01"},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Mixed Phenotype Acute Leukemia"],"enrollment":850,"completionDate":"2039-05"},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":288,"completionDate":"2029-12-31"},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":["Plasma Cell Myeloma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma"],"enrollment":1450,"completionDate":"2027-12-31"},{"nctId":"NCT04977427","phase":"PHASE4","title":"Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2021-08-31","conditions":["Cataract Diabetic","Macula Edema"],"enrollment":0,"completionDate":"2021-12-20"},{"nctId":"NCT03283917","phase":"PHASE1","title":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-07","conditions":["Newly Diagnosed Primary Amyloidosis","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis"],"enrollment":21,"completionDate":"2027-05-18"},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":["T-cell Acute Lymphoblastic Leukemia","T-cell Lymphoma","Mixed Phenotype Acute Leukemia"],"enrollment":100,"completionDate":"2033-12"},{"nctId":"NCT04764942","phase":"PHASE1,PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":39,"completionDate":"2027-12-17"},{"nctId":"NCT07428369","phase":"PHASE2,PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":["Multiple Myeloma (MM)"],"enrollment":1570,"completionDate":"2038-05-21"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT05530421","phase":"PHASE2","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-03-26","conditions":["Relapsed and Refractory Multiple Myeloma"],"enrollment":33,"completionDate":"2030-03-26"},{"nctId":"NCT05972135","phase":"PHASE2","title":"Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-10-23","conditions":["Multiple Myeloma"],"enrollment":100,"completionDate":"2027-10"},{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":["Corneal Edema","Corneal Defect","Anterior Chamber Inflammation","Ocular Pain","Corneal Staining","Visual Outcome","CME - Cystoid Macular Edema"],"enrollment":50,"completionDate":"2025-02-05"},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":21,"completionDate":"2028-02-01"},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":["Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA"],"enrollment":158,"completionDate":"2029-06-30"},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":["Multiple Myeloma"],"enrollment":18,"completionDate":"2026-09"},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":["AL Amyloidosis"],"enrollment":11,"completionDate":"2026-07-24"},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Burkitt Leukemia","Recurrent Burkitt Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Acute Lymphoblastic Leukemia","Refractory Burkitt Leukemia","Refractory Burkitt Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Lymphoblastic Lymphoma"],"enrollment":42,"completionDate":"2027-08-01"},{"nctId":"NCT04432597","phase":"PHASE1,PHASE2","title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-11","conditions":["HPV Positive Cancer","Vulvar, Vaginal, Penile, Rectal Cancer","Anal Cancer","Oropharyngeal Cancer","Cervical Cancer"],"enrollment":39,"completionDate":"2026-03-31"},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":128,"completionDate":"2034-05"},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":["Mantle Cell Lymphoma"],"enrollment":51,"completionDate":"2027-03-22"},{"nctId":"NCT06132685","phase":"PHASE2","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-09","conditions":["Low Grade Glioma","Malignant Brain Glioma","Malignant Brain Neoplasm","Meningioma"],"enrollment":200,"completionDate":"2028-07-30"},{"nctId":"NCT04661137","phase":"PHASE2","title":"A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma","status":"SUSPENDED","sponsor":"Hackensack Meridian Health","startDate":"2021-03-16","conditions":["Multiple Myeloma"],"enrollment":96,"completionDate":"2027-02"},{"nctId":"NCT05488847","phase":"PHASE4","title":"Opioid-Free Pain Protocol After Shoulder Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2022-06-25","conditions":["Shoulder Arthropathy","Shoulder Pain"],"enrollment":83,"completionDate":"2026-09-01"},{"nctId":"NCT04371445","phase":"PHASE4","title":"Dextenza in the Post-op Management of Vitreoretinal Surgeries","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-06-01","conditions":["Vitreoretinal Surgery","Ocular Inflammation","Post-operative Pain","Post-Operative Inflammation"],"enrollment":30,"completionDate":"2026-05-01"},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":["Multiple Myeloma"],"enrollment":94,"completionDate":"2027-12-31"},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":["Plasmacytoma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":35,"completionDate":"2024-07-24"},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":["B-Cell Non-Hodgkin Lymphoma (B-NHL)"],"enrollment":216,"completionDate":"2027-05-14"},{"nctId":"NCT07390097","phase":"PHASE4","title":"Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins","status":"NOT_YET_RECRUITING","sponsor":"Oguz Arslanturk","startDate":"2026-02-28","conditions":["Varicose Veins Leg","Great Saphenous Vein Insufficiency","Chronic Venous Insufficiency"],"enrollment":250,"completionDate":"2026-11"},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":["Multiple Myeloma"],"enrollment":177,"completionDate":"2027-08"},{"nctId":"NCT06489626","phase":"PHASE4","title":"The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty","status":"WITHDRAWN","sponsor":"F. Johannes Plate","startDate":"2025-11-01","conditions":["Arthritis Knee","Knee Osteoarthritis","Pain, Postoperative"],"enrollment":0,"completionDate":"2027-12-01"},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":["ISS Stage III Plasma Cell Myeloma","Multiple Myeloma"],"enrollment":17,"completionDate":"2028-11-20"},{"nctId":"NCT06988488","phase":"PHASE1,PHASE2","title":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-10-07","conditions":["Multiple Myeloma"],"enrollment":62,"completionDate":"2027-06-03"},{"nctId":"NCT04414475","phase":"PHASE2","title":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-07-01","conditions":["Multiple Myeloma, Refractory"],"enrollment":127,"completionDate":"2028-01"},{"nctId":"NCT05981209","phase":"PHASE1","title":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","status":"RECRUITING","sponsor":"Abdullah Khan","startDate":"2023-12-21","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":27,"completionDate":"2026-12-31"},{"nctId":"NCT07378215","phase":"PHASE4","title":"The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study","status":"NOT_YET_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2026-02","conditions":["Postoperative Quality of Recovery","Health-Related Quality-of-Life","Quality of Life"],"enrollment":224,"completionDate":"2027-02"},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":["Multiple Myeloma"],"enrollment":50,"completionDate":"2026-03-30"},{"nctId":"NCT05016947","phase":"PHASE1","title":"Venetoclax Plus Inotuzumab for B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-09-24","conditions":["B-cell Acute Lymphoblastic Leukemia","B-Cell Lymphoma","ALL"],"enrollment":23,"completionDate":"2026-12-23"},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":["Recurrent Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hairy Cell Leukemia","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent T Acute Lymphoblastic Leukemia","Refractory Acute Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Hairy Cell Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory T Acute Lymphoblastic Leukemia","Systemic Mastocytosis"],"enrollment":13,"completionDate":"2025-08-05"},{"nctId":"NCT07216820","phase":"NA","title":"Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-01-21","conditions":["Shoulder Surgery","Obesity"],"enrollment":68,"completionDate":"2027-11-15"},{"nctId":"NCT04240054","phase":"PHASE2","title":"Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-02","conditions":["Multiple Myeloma"],"enrollment":41,"completionDate":"2030-12-01"},{"nctId":"NCT05720949","phase":"PHASE4","title":"Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2023-01-12","conditions":["ACL","Anterior Cruciate Ligament Injuries"],"enrollment":192,"completionDate":"2024-12-02"},{"nctId":"NCT06616584","phase":"PHASE2,PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":378,"completionDate":"2028-12-31"},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":["Acute Lymphoblastic Leukemia, Pediatric"],"enrollment":560,"completionDate":"2034-11"},{"nctId":"NCT02718833","phase":"PHASE2","title":"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2016-06-21","conditions":["Multiple Myeloma"],"enrollment":52,"completionDate":"2027-12"},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":["Multiple Myeloma"],"enrollment":729,"completionDate":"2026-12"},{"nctId":"NCT02813135","phase":"PHASE1,PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":["Pediatric Cancer"],"enrollment":472,"completionDate":"2031-02"},{"nctId":"NCT01562405","phase":"PHASE1","title":"Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":["Multiple Myeloma"],"enrollment":33,"completionDate":"2027-12"},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":["Multiple Myeloma","Triple Negative Breast Cancer","Duffy Blood Group, Chemokine Receptor Gene Mutation","Duffy Blood Group, Chemokine Receptor Gene C.-67T>C"],"enrollment":90,"completionDate":"2029-03-31"},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":["Multiple Myeloma"],"enrollment":46,"completionDate":"2025-10"},{"nctId":"NCT06207305","phase":"PHASE1,PHASE2","title":"A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-30","conditions":["Metastatic Appendiceal Adenocarcinoma","Intraperitoneal Paclitaxel"],"enrollment":39,"completionDate":"2028-01-02"},{"nctId":"NCT06627751","phase":"PHASE2","title":"Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2025-05-01","conditions":["Extramedullary Disease in Multiple Myeloma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":28,"completionDate":"2030-05-01"},{"nctId":"NCT03995628","phase":"PHASE2","title":"Steroids and Pain Control After Tonsillectomy","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-12-18","conditions":["Tonsillitis","Obstructive Sleep Apnea of Child"],"enrollment":163,"completionDate":"2025-12-31"},{"nctId":"NCT03030261","phase":"PHASE2","title":"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-11-22","conditions":["Multiple Myeloma in Relapse"],"enrollment":25,"completionDate":"2027-09-26"},{"nctId":"NCT03808610","phase":"PHASE1,PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT02106988","phase":"PHASE2","title":"Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-16","conditions":["Lymphoma"],"enrollment":40,"completionDate":"2034-01-31"},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":160,"completionDate":"2026-10-31"},{"nctId":"NCT03702725","phase":"PHASE1","title":"Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2019-08-29","conditions":["Refractory Multiple Myeloma","Multiple Myeloma in Relapse","Multiple Myeloma"],"enrollment":14,"completionDate":"2024-10-04"},{"nctId":"NCT07072585","phase":"PHASE2,PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":["Stage II T Lymphoblastic Leukemia/Lymphoma","Stage III T Lymphoblastic Leukemia/Lymphoma","Stage IV T Lymphoblastic Leukemia/Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1708,"completionDate":"2035-09-01"},{"nctId":"NCT03583255","phase":"PHASE2","title":"Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-06-29","conditions":["Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphoid System Neoplasm","Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Recurrent Malignant Solid Neoplasm"],"enrollment":99,"completionDate":"2027-12-31"},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":["Multiple Myeloma"],"enrollment":100,"completionDate":"2028-12-01"},{"nctId":"NCT06383572","phase":"PHASE1,PHASE2","title":"Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-26","conditions":["Lymphodepleting Chemotherapy","Myeloid Malignancies"],"enrollment":44,"completionDate":"2029-04-01"},{"nctId":"NCT01665794","phase":"PHASE1,PHASE2","title":"Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-08-13","conditions":["Multiple Myeloma"],"enrollment":25,"completionDate":"2025-11-14"},{"nctId":"NCT02343042","phase":"PHASE1,PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":["Multiple Myeloma"],"enrollment":300,"completionDate":"2027-04"},{"nctId":"NCT04009109","phase":"PHASE2","title":"Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2020-10-21","conditions":["Myeloma, Multiple"],"enrollment":79,"completionDate":"2027-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166481","NDDF":"004294","UNII":"5921X1560Q","INN_ID":"2617","RXNORM":"1049383","UMLSCUI":"C0006694","chemblId":"CHEMBL2106191","ChEMBL_ID":"CHEMBL2106191","KEGG_DRUG":"D07427","PUBCHEM_CID":"29963","MESH_DESCRIPTOR_UI":"D002123"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":310,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C05BX01","allCodes":["C05BX01","C05BX51"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 21","pmid":"41864866","title":"Effect of calcium dobesilate on intraretinal cysts and exudates in non-proliferative diabetic retinopathy: a Fiji ImageJ analysis.","journal":"BMC ophthalmology"},{"date":"2026 Jan","pmid":"41821279","title":"Effect of calcium dobesilate on liver regeneration in rats undergoing partial hepatectomy.","journal":"Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES"},{"date":"2026 Mar","pmid":"41634981","title":"Calcium Dobesilate Interference in Two Urinary Total Protein Detection Methods.","journal":"Journal of clinical laboratory analysis"},{"date":"2026 Jan 21","pmid":"41564121","title":"The Efficacy of Calcium Dobesilate Alone or with Vascularized Lymph Node Transfer in Lymphedema Treatment: A Preliminary Study.","journal":"Plastic and reconstructive surgery"},{"date":"2025 Dec","pmid":"41523513","title":"Diverse and Atypical Presentations of Acroangiodermatitis of Mali: Diagnostic Insights From Three Cases.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:02:25.423942+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}